Mathilde Tardieu
Overview
Explore the profile of Mathilde Tardieu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belbezier A, Tardieu M, Sturm N, Charles J, Leccia M
J Inherit Metab Dis
. 2025 Feb;
48(2):e70012.
PMID: 39980398
No abstract available.
2.
Maillet C, Boccara O, Mallet S, Bessis D, Labreze C, Mary-Prey S, et al.
J Eur Acad Dermatol Venereol
. 2024 Nov;
PMID: 39584318
Rationale: Sirolimus is a treatment for slow-flow vascular malformations (SFVMs). However, the long-term management remains challenging. Objectives: The SIROLO study assessed the long-term effects and real-life management of oral sirolimus...
3.
Tardieu M, Neron A, Duvert-Lehembre S, Larabi I, Barkaoui M, Emile J, et al.
Pediatr Blood Cancer
. 2021 Jun;
68(9):e29140.
PMID: 34109735
Background: The somatic BRAF mutation occurs in 38-64% of pediatric cases of Langerhans cell histiocytosis (LCH). Vemurafenib (VMF), a BRAF inhibitor, was approved for refractory BRAF mutated LCH. In adults,...
4.
Villani A, Rozieres A, Bensaid B, Eriksson K, Mosnier A, Albert F, et al.
Sci Adv
. 2021 Mar;
7(12).
PMID: 33741590
Toxic epidermal necrolysis (TEN) is a life-threatening cutaneous adverse drug reaction. To better understand why skin symptoms are so severe, we conducted a prospective immunophenotyping study on skin and blood....
5.
Donadieu J, Larabi I, Tardieu M, Visser J, Hutter C, Sieni E, et al.
J Clin Oncol
. 2019 Sep;
37(31):2857-2865.
PMID: 31513482
Purpose: Off-label use of vemurafenib (VMF) to treat mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. Patients And Methods: Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They...
6.
Bondier L, Tardieu M, Leveque P, Challende I, Pinel N, Leccia M
Am J Dermatopathol
. 2017 Jun;
39(9):682-688.
PMID: 28609342
Cutaneous collagenous vasculopathy is a recently described idiopathic microangiopathy characterized by acquired diffuse cutaneous telangiectasias and specific histological features: dilated capillaries in the superficial dermis, with walls thickened by hyaline...
7.
van den Bruck R, Weil P, Ziegenhals T, Schreiner P, Juranek S, Godde D, et al.
Mol Cell Pediatr
. 2017 May;
4(Suppl 1):5.
PMID: 28516419
No abstract available.
8.
Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Soder S, et al.
J Invest Dermatol
. 2016 Jul;
136(11):2150-2157.
PMID: 27375110
Severe generalized junctional epidermolysis bullosa, a lethal hereditary blistering disorder, is usually treated by palliative care. Allogeneic stem cell transplantation (SCT) has been proposed as a therapeutic approach, yet without...
9.
Charles J, Beani J, Tardieu M, Busser B
J Am Acad Dermatol
. 2015 Jun;
73(1):e31.
PMID: 26089071
No abstract available.
10.
Tardieu M, Rybojad M, Peffault de Latour R, Robin M, de Masson A, Xhaard A, et al.
Blood
. 2013 Jul;
122(3):463-5.
PMID: 23869081
No abstract available.